Postmenopausal breast cancer
Conditions
Interventions
1st time:Two shots of Fulvestrant are injected to each buttock sequentially 2nd time:Those are injected to each buttock simultaneously 3rd Time and after:Those are injected to each buttock according
choice
1st time:Two shots of Fulvestrant are injected to each buttock simultanously 2nd time:Those are injected to each buttock sequentially 3rd Time and after:Those are injected to each buttock a
Sponsors
Yokohama City University Medical Center
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1)Postmenopausal patients requiring Fulvastrant clinically patients who fulfill at least one of the following as a condition of menopause; a:50 years of age or older b:less than 50 years old and in the range of post-menopausal estradiol and FSH c:patients receiving ovarian submission 2)From 50- to 75-years old 3)ECOG performance status of 0-2 4)Written informed consent obtained
Exclusion criteria
Exclusion criteria: 1)Patients who are impossible to be enrolled with psychological diseases or disorder 2)Inappropriate patients by investigator' decision
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1) Visual analog scales for simultaneous and sequential injections of Fulverant 2) Patient choice of injection method of Fulverant for 3rd time and after | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Time for injections 2) Questionnaire to patients regarding each injection method 3) Questionnaire to nurses regarding each injection method | — |
Countries
Japan
Contacts
Public ContactKazutaka Narui
Yokohama City University Medical Center Breast and thyroid surgery
Outcome results
None listed